TUSTIN, Calif., May 22 /PRNewswire-FirstCall/ -- AMDL, Inc. , (http://www.amdl.com ), a world leader in specialty pharmaceuticals with operations in Shenzhen, Jiangxi and Jilin, China, announced today that it has made available the AMDL executive management comments from its Q1 2008 financial results conference call. The document can be accessed via AMDL’s corporate website at www.amdl.com. Click on “Investor Relations,” then “Recent News.”
The posted conference call script outlines prepared remarks AMDL’s executive management made covering the Company’s financial results for the first quarter of FY2008 and the subsequent question and answers from shareholders.
About AMDL:
AMDL, Inc. is a global specialty pharmaceutical company. The company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The company employs approximately 320 people in the U.S. and China. More information about AMDL and its products can be obtained at http://www.amdl.com .
About Jade Pharmaceutical:
JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
IR Contact: Mr. Paul Knopick
CONTACT: Mr. Paul Knopick, +1-949-707-5365, Voicemail, +1-714-505-4460,
for AMDL, Inc.
Web site: http://www.amdl.com/
